Bard Financial Services Inc. Purchases 21,950 Shares of GSK plc (NYSE:GSK)

Bard Financial Services Inc. lifted its holdings in GSK plc (NYSE:GSK) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,095 shares of the pharmaceutical company’s stock after acquiring an additional 21,950 shares during the period. Bard Financial Services Inc.’s holdings in GSK were worth $2,675,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GSK. Sunbelt Securities Inc. boosted its holdings in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of GSK by 9.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 303 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its position in GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after buying an additional 323 shares in the last quarter. Rehmann Capital Advisory Group boosted its holdings in GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares in the last quarter. Finally, Investment Partners Asset Management Inc. increased its holdings in shares of GSK by 2.3% during the third quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock valued at $636,000 after acquiring an additional 344 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of NYSE GSK traded up $0.55 during mid-day trading on Monday, reaching $34.02. 2,200,021 shares of the company’s stock were exchanged, compared to its average volume of 2,340,002. The firm has a market capitalization of $70.51 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The firm has a 50-day moving average price of $34.75 and a two-hundred day moving average price of $38.40. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.62%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 98.70%.

Analysts Set New Price Targets

Several analysts recently issued reports on GSK shares. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.